Shanghai Junshi Biosciences (HKG:1877, SHA:688180) will conduct clinical trials on the drug, WJ47156 tablets, after securing the approval of the Chinese drug regulator, the National Medical Products Administration, according to a Thursday disclosure on the Hong Kong Stock Exchange.
The pharmaceutical company will test the drug as a monotherapy for the treatment of advanced malignant tumors, the disclosure said.
The company's shares soared more than 10% on the Hong Kong bourse and jumped less than 6% on the Shanghai bourse.
Price (HKD): $13.46, Change: $+1.2, Percent Change: +10.15%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments